Biopharmaceutical company MediciNova, Inc. recently completed enrollment of the first 30 patients with amyotrophic lateral sclerosis (ALS) for its clinical trial to evaluate the efficacy MN-166 (ibudilast). The company plans to add another 30 participants…

The first app for amyotrophic lateral sclerosis (ALS) patients who have begun to lose their speaking abilities was recently launched by UK company Therapy Box. The app was designed to substitute standard text-to-speech synthesis with a synthesizer based on the patient’s own voice. The Predictable 4 app has entered the ModelTalker program, at a…

Dr. Nancy Bonini A recent editorial published in the journal Neurology highlights the existing scope of clinical knowledge concerning genetic susceptibility that makes individuals prone to developing amyotrophic lateral sclerosis (ALS). The editorial content was based on a thorough…

Newron Pharmaceuticals is about to initiate its Phase II clinical trial, designed to evaluate novel molecule sNN0029 in patients who suffer from Amyotrophic Lateral Sclerosis (ALS), according to information provided by the company in a press release. The company, which has been dedicated to providing CNS…

Treeway, a biotechnological company based in the Netherlands, founded by Bernard Muller and Robbert Jan Stuit, who are both entrepreneurs and both diagnosed with amyotrophic lateral sclerosis (ALS), recently announced a collaboration with uniQure, a Dutch company specialized in gene therapy to develop a treatment for the disease.

AB Science SA, a pharmaceutical company focused on research, advancement and commercialization of protein kinase inhibitors (PKIs) announced that the external Data and Safety Monitoring Board (DSMB) recommended the company’s phase 3 study of masitinib in amyotrophic lateral sclerosis (ALS) be continued. The decision was supported by the drug’s latest safety reports. The current…

New York and Israel-based, BrainStorm Cell Therapeutics, Inc., announced positive final results from a clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS). The study reached its main goal, showing that NurOwn™ is safe and well-tolerated. In addition, the majority of the 14 participants in this study had an improvement (slowing)…

A $30 million alliance between Biogen Idec and Columbia University Medical Center was formed to conduct research in genetics and to understand the underlying causes of several diseases such as amyotrophic lateral sclerosis (ALS). This new partnership may help identify new treatment approaches to address the largely unmet clinical needs…

The U.S. Patent and Trademark Office (USPTO) recently granted clinical stage biopharmaceutical company and subsidiary of Allied Minds, SciFluor Life Sciences, LLC, a patent for one of their novel pipeline compounds, SF0034, a potent and selective neuronal potassium channel activator that is being studied for the treatment of epilepsy, amyotrophic lateral sclerosis…

Clinical-stage biopharmaceutical company Cytokinetics presented their lead drug candidate for the treatment of amyotrophic lateral sclerosis (ALS), a novel skeletal muscle activator called tirasemtiv, in an oral presentation and four poster presentations, at the 25th International Symposium on ALS/MND, which took place between December 5 and…